<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04490681</url>
  </required_header>
  <id_info>
    <org_study_id>4-2020-0484</org_study_id>
    <nct_id>NCT04490681</nct_id>
  </id_info>
  <brief_title>Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)</brief_title>
  <official_title>Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on recent studies demonstrating SGLT2 inhibitors' favorable effects on cardiovascular&#xD;
      outcomes especially for heart failure, the investigators hypothesize that sodium-glucose&#xD;
      co-transporter-2 (SGLT2) inhibitor, ertugliflozin, is effective on reducing cardiac fibrosis&#xD;
      in patients with nonischemic cardiomyopathy so the investigators try to examine this&#xD;
      hypothesis in a single-center, double-blind, randomized controlled study using cardiac&#xD;
      magnetic resonance (CMR).&#xD;
&#xD;
      This study is a prospective, single-center, randomized, double-blind, two arm parallel group,&#xD;
      placebo-controlled clinical trial involving patients with nonischemic cardiomyopathy.&#xD;
      Patients meeting inclusion criteria without any exclusion criteria will be randomized 1:1 to&#xD;
      ertugliflozin or placebo therapy, and cardiovascular functional assessment and clinical event&#xD;
      follow-up will be undertaken.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects : Patients with non-ischemic cardiomyopathy who need medical treatment Procedures :&#xD;
      This is a prospective, randomized trial to compare cardiopulmonary motor tests, cardiac MRI&#xD;
      including myocardial fibrosis parameters (ECV, etc.), and incidence of various heart&#xD;
      failure-related cardiovascular events during the follow-up period between patients with&#xD;
      ertugliflozin drug therapy and placebo drug. Patients meeting inclusion criteria without any&#xD;
      exclusion criteria will be randomized 1:1 to ertugliflozin (5mg) or placebo therapy.&#xD;
      Randomization will be stratified according to presence of diabetes mellitus, and the upper&#xD;
      limit of randomized non-DM patients will be set as 36 patients (70%). The estimated&#xD;
      enrollment period is 18 months (n=52) and all patients will be followed for 12 months after&#xD;
      randomization. Random assignment is performed at random assignment visit (V1) through eCASE&#xD;
      web system and following study procedures will be conducted according to the randomization.&#xD;
      CMR, Cardiopulmonary exercise test, serum biomarkers, and clinical endpoints will be measured&#xD;
      at 3,6,12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Due to the nature of randomized study, it will be masked to all participants, care providers, investigators, and outcomes assessors.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The ECV value change in CMR after Drug (Ertugliflozin or Placebo) administration</measure>
    <time_frame>Baseline</time_frame>
    <description>The ECV value change in MRI from baseline to End of trial (48 weeks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The ECV value change in CMR after Drug (Ertugliflozin or Placebo) administration</measure>
    <time_frame>48 Weeks after drug administration</time_frame>
    <description>The ECV value change in MRI from baseline to End of trial (48 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : ECV (%)</measure>
    <time_frame>baseline</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : ECV (%)</measure>
    <time_frame>12 weeks after drug administration</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : ECV (%)</measure>
    <time_frame>48 weeks after drug administration</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : Native T1 (ms)</measure>
    <time_frame>baseline</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : Native T1 (ms)</measure>
    <time_frame>12 weeks after drug administration</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : Native T1 (ms)</measure>
    <time_frame>48 weeks after drug administration</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : left &amp; right ventricular (LV &amp; RV) mass index (g/m2)</measure>
    <time_frame>Baseline</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : left &amp; right ventricular (LV &amp; RV) mass index (g/m2)</measure>
    <time_frame>12 weeks after drug administration</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : left &amp; right ventricular (LV &amp; RV) mass index (g/m2)</measure>
    <time_frame>48 weeks after drug administration</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : LV &amp; RV ejection fraction (%)</measure>
    <time_frame>Baseline</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : LV &amp; RV ejection fraction (%)</measure>
    <time_frame>12 weeks after drug administration</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : LV &amp; RV ejection fraction (%)</measure>
    <time_frame>48 weeks after drug administration</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume (ml)</measure>
    <time_frame>Baseline</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume (ml)</measure>
    <time_frame>12 weeks after drug administration</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume (ml)</measure>
    <time_frame>48 weeks after drug administration</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : cine-base cardiac strain (%)</measure>
    <time_frame>Baseline</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : cine-base cardiac strain (%)</measure>
    <time_frame>12 weeks after drug administration</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters : cine-base cardiac strain (%)</measure>
    <time_frame>48 weeks after drug administration</time_frame>
    <description>CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left &amp; right ventricular (LV &amp; RV) mass index), ventricular functional markers (LV &amp; RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV &amp; RV end-systolic volume, LV &amp; RV end-diastolic volume). These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers : NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7</measure>
    <time_frame>baseline</time_frame>
    <description>The change in degree of NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7 after drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers : NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7</measure>
    <time_frame>12 weeks after drug administration</time_frame>
    <description>The change in degree of NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7 after drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers : NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7</measure>
    <time_frame>24 weeks after drug administration</time_frame>
    <description>The change in degree of NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7 after drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers : NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7</measure>
    <time_frame>48 weeks after drug administration</time_frame>
    <description>The change in degree of NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7 after drug administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Heart Failure With Nonischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin</intervention_name>
    <description>Fixed dose Ertugliflozin (5mg)</description>
    <arm_group_label>Ertugliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo group</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must agree to the study protocol and provide written informed consent&#xD;
&#xD;
          -  Outpatients ≥ 19 years, &lt;75 years of age, male or female&#xD;
&#xD;
          -  Non-diabetic or type 2 DM patients with HbA1c 7.0-10.5%&#xD;
&#xD;
          -  Patients with nonischemic cardiomyopathy (LVEF ≤40%)&#xD;
&#xD;
          -  Exclusion of ischemic origin cardiomyopathy using coronary angiography or CT&#xD;
             angiography or SPECT scan (e.g. significant stenosis of proximal LAD or left main &amp;&#xD;
             myocardial infarction)&#xD;
&#xD;
          -  Dyspnea of NYHA functional class II or III&#xD;
&#xD;
          -  NT-proBNP ≥ 400 pg/ml (≥ 900 pg/ml if atrial fibrillation or atrial flutter)&#xD;
&#xD;
          -  Titration of HF medications should be completed and patients must take a stable,&#xD;
             optimized dose of a β-blocker and an ACE inhibitor (or ARB or ARNI if indicated) for&#xD;
             at least 4 weeks prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity or allergy to the study drug, drugs of similar chemical&#xD;
             classes, or SGLT-2 as well as known or suspected contraindications to the study drug&#xD;
&#xD;
          -  Current use or prior use of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor&#xD;
&#xD;
          -  Known history of angioedema&#xD;
&#xD;
          -  Current acute decompensated heart failure or dyspnea of NYHA functional class IV&#xD;
&#xD;
          -  Medical history of hospitalization within 6 weeks&#xD;
&#xD;
          -  Acute coronary syndrome, stroke, major CV surgery, PCI within 3 months&#xD;
&#xD;
          -  Substantial myocardial ischemia requiring coronary revascularization therapy or a plan&#xD;
             of coronary revascularization within 6 months&#xD;
&#xD;
          -  A plan of heart transplantation or implantation of cardiac resynchronization therapy&#xD;
&#xD;
          -  Symptomatic hypotension and/or a SBP &lt; 95 mmHg at screening&#xD;
&#xD;
          -  Estimated GFR &lt; 30 mL/min/1.73m2&#xD;
&#xD;
          -  History of ketoacidosis&#xD;
&#xD;
          -  Symptomatic peripheral artery disease and history of lower limb amputation&#xD;
&#xD;
          -  Evidence of hepatic disease as determined by any one of the following: AST or ALT&#xD;
             values exceeding 3 x upper limit of normal (ULN) at screening visit (Visit 0), history&#xD;
             of hepatic encephalopathy, history of esophageal varices, or history of portacaval&#xD;
             shunt.&#xD;
&#xD;
          -  History of severe pulmonary disease&#xD;
&#xD;
          -  Significant mitral &amp; aortic valve disease (e.g. moderate to severe, severe degree)&#xD;
&#xD;
          -  Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, unless they are using a barrier method plus a hormonal method&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Any clinically significant abnormality identified at the screening visit, physical&#xD;
             examination, laboratory tests, or electrocardiogram which, in the judgment of the&#xD;
             investigator, would preclude safe completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seok-Min Kang</last_name>
    <phone>82-2-2228-8450</phone>
    <email>smkang@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospiatal</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Seok-Min Kang</last_name>
      <phone>82-2-2228-8450</phone>
      <email>smkang@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertugliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

